Clinical Trials Logo

Metastatic Solid Tumors clinical trials

View clinical trials related to Metastatic Solid Tumors.

Filter by:

NCT ID: NCT02045602 Completed - Clinical trials for Pancreatic Adenocarcinoma

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Start date: January 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of VCN-01 either administered alone or in combination with Abraxane®/Gemcitabine, and to determine the recommended phase II dose of VCN-01 alone or in combination with Abraxane®/Gemcitabine.

NCT ID: NCT01976143 Completed - Advanced Cancer Clinical Trials

A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety

Start date: February 2014
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to evaluate the effect of NKTR-102 on the QT/QTc interval in patients with advanced or metastatic solid tumors

NCT ID: NCT01928459 Completed - Clinical trials for Advanced Solid Tumors

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Start date: October 2013
Phase: Phase 1
Study type: Interventional

To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.

NCT ID: NCT01449370 Completed - Clinical trials for Metastatic Solid Tumors

Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer

Start date: October 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) and/or optimal biologic dose(OBD), safety and tolerability, dose-limiting toxicity (DLT) of MLN1117 when administered orally in subjects with advanced solid malignancies.

NCT ID: NCT00878423 Completed - Clinical trials for Metastatic Solid Tumors

Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors

Start date: May 2008
Phase: Phase 1
Study type: Interventional

AT13387/0001 is a dose-finding study of an experimental anticancer agent. In accordance with the protocol increasing doses of AT13387 are given to patients with advanced cancer who do not have alternative treatment options. The preferred dose of AT13387 will be identified according to the side effects experienced at different dose levels.

NCT ID: NCT00793897 Completed - Clinical trials for Advanced Solid Tumors

Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Start date: April 2009
Phase: Phase 1
Study type: Interventional

A Phase I dose escalation study to determine the safety, tolerability, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in combination with chemotherapy drugs, paclitaxel and carboplatin, in patients with advanced or metastatic solid tumors. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 in combination with paclitaxel and carboplatin for Phase 2 studies

NCT ID: NCT00670488 Completed - Cancer Clinical Trials

Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)

Start date: April 15, 2008
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to investigate the Dose Limiting Toxicities (DLTs), pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2206 administered orally to participants with advanced solid tumors. The preliminary efficacy of MK-2206 will also be investigated.